Lung Cancer | Topics

 
Erica C. Nakajima, MD, Analyzes Frontline Immune Checkpoint Inhibitors in KRAS+, PD-L1+ Non-Small Cell Lung Cancer
November 28, 2022

Erica C. Nakajima, MD, discussed a pooled analysis analyzing immune checkpoint inhibitors with or without chemotherapy in the frontline treatment of patients with KRAS-mutated non-small cell lung cancer and PD-L1 expression.

Lung Cancer Treatment & Screening
October 31, 2022

Dr. Nabil Rizk, Chief of Thoracic Surgery on increasing participation and accessibility of lung cancer screening.

Joel W. Neal, MD, PhD Discusses the Data on Cabozantinib and Atezolizumab Use in Advanced NSCLC
September 28, 2022

In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.

Improving Outcomes in Non-Small Cell Lung Cancer: Future Directions in Care
September 23, 2022

Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.

NSCLC: Treatment Options for Patients With Driver Mutations and PD-L1 Expression
September 16, 2022

Closing out their review of the second patient scenario, panelists define treatment options for NSCLC with both EGFR mutation and PD-L1 expression.

Chart Review 2: A 73-Year-Old Asian Woman With Advanced NSCLC
September 16, 2022

Expert oncologists consider how they would approach molecular testing in a 73-year-old Asian woman diagnosed with advanced non–small cell lung cancer.

Mark A. Socinski, MD, on Progression of Lung Cancer Treatment
September 13, 2022

“Opportunities to escalate therapies that work well in stage IV into what we consider a more curative setting...are exactly what we need to be looking for.” –Mark A. Socinski, MD

Adjuvant Osimertinib Yields Promising Reduction in Risk of Recurrence or Death in EGFR+ Stage IB-IIIA NSCLC
September 11, 2022

Findings from the phase 3 ADURA trial indicated that patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC) experienced a promising reduction in risk of disease recurrence or death following treatment with adjuvant osimertinib.

Study Finds Particulate Matter May Drive EGFR-Positive Non-Small Cell Lung Cancer
September 10, 2022

Findings provided rationale to limit air pollution and highlighted the need for molecularly targeted lung cancer prevention due to particulate matter being revealed as a mechanistic driver for EGFR-positive NSCLC.

Selecting Second-Line Treatment for EGFR-Mutated Advanced NSCLC
September 09, 2022

Focusing on second-line treatment options for EGFR-mutated advanced NSCLC, panelists review the use of mobocertinib and amivantamab, respectively.